TrialJournal of translational medicine2016

A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis.

Jacqueline E Paramarta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.